HARBIN BANK (06138) Enhances and Expands Agricultural Services to Support High-Quality Development of Agriculture in Heilongjiang
In the first half of 2026, Harbin Bank (06138), positioning itself as a local bank rooted in Heilongjiang, continued to fulfill its social responsibility as a financial enterprise by leveraging the region's resource endowments and agricultural industry foundation.
In the first half of 2026, HARBIN BANK (06138), positioning itself as a local bank rooted in Heilongjiang, continued to fulfill its social responsibility as a financial institution by leveraging regional resource endowments and the agricultural industry base. During the reporting period, the Group extended over RMB 13 billion in new-cycle spring plowing preparation loans; its online agricultural loan product "Nongshan Dai" achieved full coverage of county-level and reclamation area institutions across the province, with cumulative online credit disbursement exceeding RMB 10 billion; and it upgraded the "Caihong Dai" specialized agricultural service product, with financing for its distinctive customer group surpassing RMB 2 billion. Data shows that as of June 30, 2026, the Group's outstanding farmer loan balance stood at RMB 17.076 billion, with business service coverage extending to the vast majority of rural markets across 11 prefecture-level cities and 6 major agricultural reclamation bureaus in Heilongjiang Province, as well as parts of rural areas in Chengdu, Chongqing, Shenyang, Tianjin, and Dalian. The improvement in quality and expansion of coverage of agricultural benefit services not only fulfills social responsibility but also broadens business growth drivers, injecting new momentum into sustained performance growth.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH) signed a licensing agreement with Novo Nordisk A/S for the HRS-1596 project.

Jiangsu Hengrui Pharmaceuticals (01276) licenses exclusive overseas rights to HRS-1596 to Novo, with a potential transaction value of up to US$2.6 billion.

SHINEWAY PHARM (02877): Xin Yunxia will retire from the position of executive director.
Jiangsu Hengrui Pharmaceuticals (600276.SH) signed a licensing agreement with Novo Nordisk A/S for the HRS-1596 project.

Jiangsu Hengrui Pharmaceuticals (01276) licenses exclusive overseas rights to HRS-1596 to Novo, with a potential transaction value of up to US$2.6 billion.

SHINEWAY PHARM (02877): Xin Yunxia will retire from the position of executive director.






